Company profile
Chiesi Farmaceutici
Privately held: no public share price
Assets
(6 total)
6Total Assets
3Approved
2Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Small molecule | Asthma | |
Cangrelor(Kengreal) | Approved | P2Y12 receptorSmall molecule | Atherosclerotic Cardiovascular Disease |
Lomitapide(Juxtapid) | Approved | MTPSmall molecule | Atherosclerotic Cardiovascular Disease |
| Phase 3 | Glucocorticoid receptor; β2-adrenergic receptorSmall molecule | Asthma | |
metreleptin(Myalept) | Phase 3 | LeptinProtein / enzyme therapeutic | Obesity |
Melevodopa/carbidopa (Sirio)No recent activity | Phase 1/2 | dopamine precursorSmall molecule | Parkinson's Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.